Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.
For the treatment of nasal congestion, control of urinary incontinence, priapism and obesity.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.